On December 18th, the establishment of the First Plenary Meeting of the New Drug Research and Development Committee of Integrated Chinese and Western Medicine was held in the Southern Club Hotel Guanghzou. Mr. Xinhua Tao, Chairman of Leadingpharm and Executive Director of China Research Hospital Association（CRHA）, was elected as the first vice chairman.

On December 10, the project of Leadingpharm (Chongqing) Biomedical Integrated R & D Service Base was officially signed and settled. Leadingpharm will work together with Yongchuan to build a biomedical industry cluster with national influence.

Recently, the clinical test project of Human Umbilical Cord Mesenchymal Stem Cell Injection studied by the scientific research team of Qingdao Allcare Biomedical Development(ABMO) for patients with moderate and severe ulcerative colitis initiated a clinical trial in the Affiliated Hospital of Qingdao University, and subjects are recruited to the whole regions.

On December 7, 2021, Leadingpharm and China Certification & Inspection （Group）Co . , Ltd .（CCIC） signed a strategic cooperation agreement. The two sides will give full play to their respective resources and technical advantages, conduct in-depth cooperation in the field of pharmaceutical analysis and testing, and jointly build a public service platform for testing and evaluation of health product.

Recently, Leadingpharm and Huluwa Pharmaceutical Group signed a memorandum of strategic cooperation, and the two sides reached a cooperation intention on the construction of a high-end pediatric drug research institute.